Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning

por Topaly, J, Fruehauf, S, Ho, A D, Zeller, W J
Publicado 2002

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

por Lisenko, K., Dingeldein, G., Cremer, M., Kriegsmann, M., Ho, A. D., Rieger, M., Witzens-Harig, M.
Publicado 2017

Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation

por Sigl, M, Spoerl, S, Schnittger, S, Meissner, J, Rummelt, C, Peschel, C, Duyster, J, Ho, A D, von Bubnoff, N
Publicado 2013

Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

por Lisenko, K., McClanahan, F., Schöning, T., Schwarzbich, M. A., Cremer, M., Dittrich, T., Ho, A. D., Witzens-Harig, M.
Publicado 2016

Tumour necrosis factor production and natural killer cell activity in peripheral blood during treatment with recombinant tumour necrosis factor.

por Männel, D. N., Kist, A., Ho, A. D., Räth, U., Reichardt, P., Wiedenmann, B., Schlick, E., Kirchner, H.
Publicado 1989

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation

por Xu, J, Pfarr, N, Endris, V, Mai, E K, Md Hanafiah, N H, Lehners, N, Penzel, R, Weichert, W, Ho, A D, Schirmacher, P, Goldschmidt, H, Andrulis, M, Raab, M S
Publicado 2017

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

por Kayser, S, Benner, A, Thiede, C, Martens, U, Huber, J, Stadtherr, P, Janssen, J W G, Röllig, C, Uppenkamp, M J, Bochtler, T, Hegenbart, U, Ehninger, G, Ho, A D, Dreger, P, Krämer, A
Publicado 2016

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma

por Beckermann, B M, Kallifatidis, G, Groth, A, Frommhold, D, Apel, A, Mattern, J, Salnikov, A V, Moldenhauer, G, Wagner, W, Diehlmann, A, Saffrich, R, Schubert, M, Ho, A D, Giese, N, Büchler, M W, Friess, H, Büchler, P, Herr, I
Publicado 2008

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

por Chaturvedi, A, Herbst, L, Pusch, S, Klett, L, Goparaju, R, Stichel, D, Kaulfuss, S, Panknin, O, Zimmermann, K, Toschi, L, Neuhaus, R, Haegebarth, A, Rehwinkel, H, Hess-Stumpp, H, Bauser, M, Bochtler, T, Struys, E A, Sharma, A, Bakkali, A, Geffers, R, Araujo-Cruz, M M, Thol, F, Gabdoulline, R, Ganser, A, Ho, A D, von Deimling, A, Rippe, K, Heuser, M, Krämer, A
Publicado 2017

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

por Gratwohl, A, Pfirrmann, M, Zander, A, Kröger, N, Beelen, D, Novotny, J, Nerl, C, Scheid, C, Spiekermann, K, Mayer, J, Sayer, H G, Falge, C, Bunjes, D, Döhner, H, Ganser, A, Schmidt-Wolf, I, Schwerdtfeger, R, Baurmann, H, Kuse, R, Schmitz, N, Wehmeier, A, Th Fischer, J, Ho, A D, Wilhelm, M, Goebeler, M-E, Lindemann, H W, Bormann, M, Hertenstein, B, Schlimok, G, Baerlocher, G M, Aul, C, Pfreundschuh, M, Fabian, M, Staib, P, Edinger, M, Schatz, M, Fauser, A, Arnold, R, Kindler, T, Wulf, G, Rosselet, A, Hellmann, A, Schäfer, E, Prümmer, O, Schenk, M, Hasford, J, Heimpel, H, Hossfeld, D K, Kolb, H-J, Büsche, G, Haferlach, C, Schnittger, S, Müller, M C, Reiter, A, Berger, U, Saußele, S, Hochhaus, A, Hehlmann, R
Publicado 2016